NRAS mutation

Activating NRAS mutations detected by sequencing or PCR; used as a predictive marker in colorectal cancer (anti-EGFR antibodies) and studied in melanoma.

CI-BIO-00000017NRAS graph →NCIt C41381 Tumor-agnostic · 4 approval rows

Also calledNRAS-mutant · NRAS-mutated

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (13)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	17	16	1	—	1 / 6 / 8 / 2 / 0
Melanoma	15	12	2	1	0 / 6 / 6 / 3 / 0
Cutaneous Melanoma	9	9	—	—

Derived

Drugs with predictive evidence (20)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	14	—	14	A	0 / 13	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	8	8	—	B	7 / 0	Cutaneous Melanoma, Melanoma, Neuroblastoma, Solid Neoplasm
TrametinibSmall Molecule	6	6	—	B	5 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Ovarian Serous Tumor +1
SelumetinibSmall Molecule	6	6	—	B	4 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
BelvarafenibSmall Molecule	5	5	—	C	5 / 0	Acral Lentiginous Melanoma, Melanoma, Mucosal Melanoma
Chemotherapy	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	4	—	4	C	0 / 4	Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	3	—	3	B	0 / 3	Cutaneous Melanoma, Melanoma
PanitumumabMonoclonal Antibody	2	—	2	A	0 / 2	Malignant Colorectal Neoplasm
TemozolomideSmall Molecule	2	2	—	C	2 / 0	Melanoma
AmuvatinibSmall Molecule	1	1	—	D	1 / 0	Cutaneous Melanoma
DabrafenibSmall Molecule	1	—	1	B	0 / 1	Melanoma
DactolisibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
EverolimusSmall Molecule	1	1	—	D	1 / 0	Neuroblastoma
MetforminSmall Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
OmipalisibSmall Molecule	1	1	—	D	1 / 0	Melanoma
RibociclibSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
TanespimycinSmall Molecule	1	1	—	C	1 / 0	Melanoma
MEK Inhibitor RO4987655	1	—	1	C	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (47)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–47 of 47 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NRAS G13R3
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13214 A patient with acral melanoma harboring NRAS G13R received belvarafenib monotherapy after four prior lines of systemic therapy and achieved stable disease as the best RECIST response. The patient rece… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID2204 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID3842 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61K8
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13218 A patient with acral melanoma harboring NRAS Q61K received belvarafenib as first-line therapy for metastatic disease after progression on adjuvant pembrolizumab and achieved stable disease as the best… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1475 Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acqui… (full text at CIViC) PMID 22194965 · Atefi et al., 2011 · Open in CIViC	civic
Vemurafenib	Cutaneous MelanomaALIAS	Predictive
NRAS Mutation14
Amuvatinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	1	accepted	EID1476 Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growt… (full text at CIViC) PMID 24950457 · Fedorenko et al., 2014 · Open in CIViC	civic
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1472 Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed). PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
〃	Cutaneous MelanomaALIAS
NRAS Q615
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1226 Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9… (full text at CIViC) PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1473 Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of se… (full text at CIViC) PMID 18390968 · Adjei et al., 2008 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER
NRAS G12D2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID3693 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2002 One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q179*1
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID4785 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
NRAS Q61R3
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID2184 Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and P… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13220 A patient with melanoma harboring NRAS Q61R received belvarafenib monotherapy after one prior line of systemic therapy and achieved stable disease as the best RECIST response. At the October 2023 data… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response
NRAS G12C1
Cetuximab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID3845 Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, an… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61L3
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2181 Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PI… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID22 In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months. PMID 21576590 · Soon et al., 2011 · Open in CIViC	civic
Belvarafenib	Mucosal Melanoma	Predictive	C	Supports Sensitivity Response
NRAS Q61H1
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID3690 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA.… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRAS BRAF NF1 KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRAS NF1 BRAF KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
NRAS G12A1
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13153 A patient with melanoma harboring NRAS G12A received belvarafenib monotherapy after two prior lines of systemic therapy and achieved a partial response as the best RECIST response. Belvarafenib treatm… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
NRAS Gain1
Binimetinib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID6899 In melanoma preclinical models, increased NRAS expression enhanced sensitivity to binimetinib in NRAS-copy-normal A875 cells, whereas NRAS knockdown decreased binimetinib sensitivity in NRAS-gain WM26… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC	civic
NRAS G13D1
Tanespimycin	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID21 Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mu… (full text at CIViC) PMID 18375819 · Banerji et al., 2008 · Open in CIViC	civic
BRAF V600E + NRAS MutationBRAF NRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6263 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (333)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Binimetinib	CA Health Canada	—	Marketed in Canada as MEKTOVI (DIN 02513080) under ATC L01EE03 BINIMETINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 5, 2021	health-canada-dpd
Cetuximab	CA Health Canada	—	Marketed in Canada as ERBITUX (DIN 02271249) under ATC L01FE01 CETUXIMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 28, 2008	health-canada-dpd
Dabrafenib	CA Health Canada	—	Marketed in Canada as TAFINLAR (DIN 02540053) under ATC L01EC02 DABRAFENIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (349)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 188 recruiting · 62 active phase 3 · 1,723 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 251–300 of 349 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04868877	Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination	active not recruiting	Phase 1 / Phase 2	194	Merus B.V.INDUSTRY	9	Feb 19, 2026	clinicaltrials
NCT03794349	Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma	active not recruiting	Phase 2	94	Children's Oncology GroupNETWORK	5	Feb 18, 2026	clinicaltrials
NCT04903119	Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma	recruiting	Phase 1	30	Rina PlattnerOTHER	1	Feb 13, 2026	clinicaltrials
NCT04478279	A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors	active not recruiting	Phase 1 / Phase 2	125	Sapience TherapeuticsINDUSTRY	2	Feb 9, 2026	clinicaltrials
NCT04884282	Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)(COMBI-TED)	active not recruiting	Phase 2	105	Fondazione Ricerca TraslazionaleOTHER	3	Feb 6, 2026	clinicaltrials
NCT03543969	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	active not recruiting	Early Phase 1	14	H. Lee Moffitt Cancer Center and Research InstituteOTHER	1	Feb 5, 2026	clinicaltrials
NCT06268015	Botensilimab and Balstilimab Optimization in Colorectal Cancer(BBOpCo)	active not recruiting	Phase 2	16	Nicholas DeVito, MDOTHER	1	Feb 5, 2026	clinicaltrials
NCT07389265	Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer(CAPRI-3 GOIM)	recruiting	Phase 3	480	University of Campania Luigi VanvitelliOTHER	2	Feb 5, 2026	clinicaltrials
NCT06440850	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation	recruiting	Phase 2	21	City of Hope Medical CenterOTHER	1	Feb 2, 2026	clinicaltrials
NCT06208657	Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer	recruiting	Phase 1 / Phase 2	90	Australian & New Zealand Children's Haematology/Oncology GroupOTHER	2	Jan 28, 2026	clinicaltrials
NCT05867420	A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.	recruiting	Phase 1 / Phase 2	594	AskGene Pharma, Inc.INDUSTRY	2	Jan 27, 2026	clinicaltrials
NCT07361484	Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)	not yet recruiting	Phase 3	442	BeyondSpring Pharmaceuticals Inc.INDUSTRY	0	Jan 23, 2026	clinicaltrials
NCT06576635	LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients(LUNG-05)	recruiting	N/A	29	University of Illinois at ChicagoOTHER	1	Jan 20, 2026	clinicaltrials
NCT03875781	Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer(NORAD01)	recruiting	Phase 3	540	Assistance Publique - Hôpitaux de ParisOTHER	1	Jan 15, 2026	clinicaltrials
NCT04689347	5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.	recruiting	Phase 1 / Phase 2	27	Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER	1	Jan 12, 2026	clinicaltrials
NCT06908304	A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC	recruiting	Phase 3	300	Maia BiotechnologyINDUSTRY	4	Jan 12, 2026	clinicaltrials
NCT07334301	A Multi-Arm, Platform Trial For Relapsed Neuroblastoma(BEACON2)	recruiting	Phase 1 / Phase 2	160	University of BirminghamOTHER	5	Jan 12, 2026	clinicaltrials
NCT07330050	WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC	recruiting	Phase 2	31	Tianjin Medical University Cancer Institute and HospitalOTHER	1	Jan 9, 2026	clinicaltrials
NCT07330596	QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC	recruiting	Phase 2	96	Anhui Provincial Cancer HospitalOTHER	1	Jan 9, 2026	clinicaltrials
NCT03983993	Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer(NIPAVect)	active not recruiting	Phase 2	26	Emory UniversityOTHER	1	Jan 5, 2026	clinicaltrials
NCT04367311	Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)	active not recruiting	Phase 2	100	Nasser HannaOTHER	1	Jan 2, 2026	clinicaltrials
NCT06102057	PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC(PACCELIO)	recruiting	Phase 2	110	TheraOpOTHER	2	Dec 17, 2025	clinicaltrials
NCT06908993	Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated(COMET)	recruiting	Phase 3	133	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Dec 17, 2025	clinicaltrials
NCT05391126	GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care	recruiting	N/A	178	Reema A. PatelOTHER	1	Dec 16, 2025	clinicaltrials
NCT06107413	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	active not recruiting	Phase 2	280	AbbVieINDUSTRY	8	Dec 12, 2025	clinicaltrials
NCT06245356	Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer(TRIFLUOX-DP)	recruiting	Phase 2	73	UNICANCEROTHER	1	Dec 10, 2025	clinicaltrials
NCT06241456	FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors	recruiting	Phase 1	351	Fate TherapeuticsINDUSTRY	1	Dec 9, 2025	clinicaltrials
NCT07271602	A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.	not yet recruiting	Phase 2	104	Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER	0	Dec 9, 2025	clinicaltrials
NCT06733038	FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.(AtezoTRIBE2)	recruiting	Phase 3	238	Gruppo Oncologico del Nord-OvestOTHER	1	Dec 8, 2025	clinicaltrials
NCT07260058	Immune Cell Therapy for Advanced Solid Tumors	not yet recruiting	Phase 1 / Phase 2	48	Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.INDUSTRY	0	Dec 2, 2025	clinicaltrials
NCT05768178	DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Nov 24, 2025	clinicaltrials
NCT03829462	Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients(NEXT-REGIRI)	active not recruiting	Phase 3	377	Institut du Cancer de Montpellier - Val d'AurelleOTHER	1	Nov 21, 2025	clinicaltrials
NCT07242274	Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC	not yet recruiting	Phase 3	472	JemincareINDUSTRY	1	Nov 21, 2025	clinicaltrials
NCT04385277	Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)	active not recruiting	Phase 2	41	Children's Oncology GroupNETWORK	4	Oct 27, 2025	clinicaltrials
NCT06228326	A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1)	recruiting	Phase 1 / Phase 2	250	Krystal Biotech, Inc.INDUSTRY	1	Oct 24, 2025	clinicaltrials
NCT04185883	Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)	active not recruiting	Phase 1	610	AmgenINDUSTRY	13	Oct 22, 2025	clinicaltrials
NCT03889795	Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors	active not recruiting	Phase 1	15	Danae Hamouda, MDOTHER	1	Oct 20, 2025	clinicaltrials
NCT05382442	A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer	active not recruiting	Phase 2	254	AkesoINDUSTRY	2	Oct 14, 2025	clinicaltrials
NCT05020457	SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.	active not recruiting	Phase 2	69	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY	1	Sep 26, 2025	clinicaltrials
NCT05216432	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer	recruiting	Phase 1	930	Relay Therapeutics, Inc.INDUSTRY	5	Sep 22, 2025	clinicaltrials
NCT05372354	A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma	recruiting	Phase 1 / Phase 2	260	Bristol-Myers SquibbINDUSTRY	5	Sep 5, 2025	clinicaltrials
NCT07134205	The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer	not yet recruiting	Phase 3	252	Shanghai JMT-Bio Inc.INDUSTRY	0	Aug 21, 2025	clinicaltrials
NCT06896422	Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC	recruiting	Phase 1	80	The First Affiliated Hospital of Zhengzhou UniversityOTHER	1	Aug 7, 2025	clinicaltrials
NCT06856187	Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer(TASBEL)	recruiting	Phase 2	119	Fudan UniversityOTHER	1	Aug 6, 2025	clinicaltrials
NCT03493048	Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM	active not recruiting	Phase 2	146	Sun Yat-sen UniversityOTHER	1	Aug 3, 2025	clinicaltrials
NCT02304809	Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations(AcSé)	active not recruiting	Phase 2	216	UNICANCEROTHER	1	Aug 1, 2025	clinicaltrials
NCT06458257	The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia	recruiting	—	50	Ruijin HospitalOTHER	1	Jul 29, 2025	clinicaltrials
NCT05755672	On-treatment Biomarkers in Metastatic Colorectal Cancer for Life(On-CALL)	recruiting	—	100	Region SkaneOTHER	1	Jul 17, 2025	clinicaltrials
NCT07069933	Repurposing Itraconazole as an Adjuvant Therapy in Treatment of Patients With Acute Myeloid Leukemia: Is it a Hopeful Avenue for Enhancing Treatment Options?	not yet recruiting	Phase 2	50	Mansoura UniversityOTHER	1	Jul 17, 2025	clinicaltrials
NCT07062263	Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2)	recruiting	Phase 3	220	Tata Memorial CentreOTHER	1	Jul 14, 2025	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (13)

Drugs with predictive evidence (20)

Predictive evidence items (47)

Approvals mentioning the linked drugs (333)

Active trials (349)

Linked publications (37)